CRUS
Cirrus Logic, Inc.
CRUS trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over CRUS overall, supported by stronger modeled upside and stronger valuation.
CRUS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
CRUS's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CRUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 15x | $122 | — |
| Cheap | 16x | $128 | +4.8% |
| Fair | 21x | $168 | +38% |
| Expensive | 28x | $219 | +80% |
Historical ranges are pointers, not guarantees.
CRUS's PE is in its cheap range at 15x.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over CRUS in the historical PE scenario, which offers more potential upside but is not a forecast.
CRUS Forward outlook
There aren't enough analyst estimates for CRUS to show an outlook.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
CRUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $7.93 | +13% |
| Q2 2026 | $8.18 | +28% |
| Q1 2026 | $7.85 | +31% |
| Q4 2025 | $7.58 | +38% |
| Q3 2025 | $7.03 | +20% |
| Q2 2025 | $6.38 | +19% |
| Q1 2025 | $6.00 | +22% |
| Q4 2024 | $5.48 | +73% |
CRUS's earnings per share have climbed steadily: $7.93 over the past year, up 13% from the year before, and higher year over year for 11 quarters in a row.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CRUS on earnings, with stronger typical year-over-year growth.
CRUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $559.5M | -0.3% |
| Q2 2026 | $459.7M | +13% |
| Q1 2026 | $448.5M | +5.7% |
| Q4 2025 | $580.6M | +4.5% |
| Q3 2025 | $561M | +3.5% |
| Q2 2025 | $407.3M | +8.9% |
| Q1 2025 | $424.5M | +14% |
| Q4 2024 | $555.7M | -10% |
CRUS's revenue is growing: $559M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -2.1 points |
| Q2 2026 | 18% | +0.6 points |
| Q1 2026 | 20% | -0.1 points |
| Q4 2025 | 26% | +0.1 points |
| Q3 2025 | 26% | +1.5 points |
| Q2 2025 | 18% | +5.3 points |
| Q1 2025 | 20% | +6.2 points |
| Q4 2024 | 26% | -0.8 points |
CRUS's operating margin was 24% last quarter, down 2.1 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over CRUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over CRUS on profitability, with a higher operating margin.
CRUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $42.5M | -52% |
| Q2 2026 | $49M | -57% |
| Q1 2026 | $149M | +17% |
| Q4 2025 | $285.7M | +35% |
| Q3 2025 | $88.3M | +1489% |
| Q2 2025 | $113.5M | +47% |
| Q1 2025 | $127M | -22% |
| Q4 2024 | $211.9M | -30% |
CRUS generated $526M in free cash flow over the past year, down 2.7% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over CRUS on cash flow, with more consistent year-over-year improvement.
CRUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -872K shares |
| 1 year | -3% | -1.6M shares |
| 3 years | -8.5% | -4.8M shares |
| 5 years | -13% | -8M shares |
| Available history | -15% | -9M shares |
CRUS has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $128.5M |
| Q2 2026 | $31.5M |
| Q1 2026 | $70M |
| Q4 2025 | $70M |
| Q3 2025 | $40M |
| Q2 2025 | $100M |
| Q1 2025 | $100M |
| Q4 2024 | $70M |
CRUS spent $300M buying back its own shares over the past year, down 3.2% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CRUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.4x | Net Cash |
| Q2 2026 | -1.5x | Net Cash |
| Q1 2026 | -1.6x | Net Cash |
| Q4 2025 | -1.5x | Net Cash |
| Q3 2025 | -1.2x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -1.2x | Net Cash |
CRUS has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CRUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.1 | Neutral |
| Stochastic | 41.1 | Neutral |
CRUS's weekly RSI is 47 (neutral) and its Stochastic is 41 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CRUS PE vs Technology Sector
| Metric | CRUS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 28x | 45% below |
| PE % | 15 | 35 | 20 pts below |
CRUS has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
CRUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $114.2 | 6.6% above |
| 20 week MA | $121.6 | 0.1% above |
| 50 week MA | $135.7 | 10% below |
| 100 week MA | $121.5 | 0.2% above |
| 200 week MA | $108.8 | 12% above |
CRUS has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
CRUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $83.4 | $81.0 | -2.9% |
| 2021 | $81.0 | $91.5 | +13% |
| 2022 | $91.5 | $75.0 | -18% |
| 2023 | $75.0 | $83.2 | +11% |
| 2024 | $83.2 | $101.9 | +22% |
| 2025 | $101.9 | $120.9 | +19% |
| 2026 YTD | $120.9 | $121.7 | +0.7% |
CRUS has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.